Karyopharm posts results for selinexor trial testing hepatic impairment dosing, combinations

Karyopharm Therapeutics had one update of note this week: results posted for its multi-arm selinexor study.

• Karyopharm posted results for "SPRINT" (NCT04256707), a completed Phase 1/2 trial of selinexor. The study enrolled patients with normal hepatic function who had non-small cell lung cancer or colorectal cancer, as well as patients with impaired hepatic function and any solid tumor who had at least one prior line of treatment.¹ The trial included two treatment periods, monotherapy and combination therapy.¹ During monotherapy, the study compared bioavailability of 100 mg and 20 mg selinexor tablet formulations, and assessed pharmacokinetics of selinexor in patients with moderate and severe hepatic impairment versus normal hepatic function.¹ The combination period evaluated preliminary antitumor activity of selinexor combined with docetaxel in NSCLC patients and with pembrolizumab or FOLFIRI in colorectal cancer patients.¹ The study planned to enroll up to 120 patients, with up to 106 patients with normal hepatic function receiving combination therapy.¹ Primary completion and study completion were both dated 2024-07-31.